AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6204142 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake (200 mmol) in subjects over 50 years
Number of subjects: 201
Study 6204142 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake (200 mmol) in younger individuals
Number of subjects: 201
Study 6204142 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sodium intake
Number of subjects: 201
Study 6204142 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced sodium intake
Number of subjects: 201
Study 30630702 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving‐Adherence (PSA)
Number of subjects: 87
Study 30630702 — intervention group
Group type: COMPARATOR
Intervention: Personalized Intervention for Depressed Patients with COPD (PID‐C)
Number of subjects: 87
Study 29713133 — intervention group
Group type: COMPARATOR
Intervention: Catheter and guidewire (Group I)
Number of subjects: 102
Study 29713133 — intervention group
Group type: EXPERIMENTAL
Intervention: Papillary fistulotomy (Group II)
Number of subjects: 102
Study 26938358 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intake self-management
Number of subjects: 180
Study 26938358 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intake self-efficacy
Number of subjects: 180
Study 24163264 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (0.4 U/kg, single subcutaneous dose)
Number of subjects: 30
Study 22253751 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and physical program (Intervention Group)
Number of subjects: 1913
Study 22253751 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control Group)
Number of subjects: 1913
Study 19953628 — intervention group
Group type: EXPERIMENTAL
Intervention: Provox Normal HME (R‐HME)
Number of subjects: 11
Study 19953628 — intervention group
Group type: EXPERIMENTAL
Intervention: Provox HiFlow HME (L‐HME)
Number of subjects: 11
Study 19953628 — intervention group
Group type: COMPARATOR
Intervention: Without HME
Number of subjects: 11
Study 17473095 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for >2 weeks
Number of subjects: 150
Study 17473095 — intervention group
Group type: COMPARATOR
Intervention: Exclusive breastfeeding for <=2 weeks
Number of subjects: 150
Study 17473095 — intervention group
Group type: EXPERIMENTAL
Intervention: High maternal antibody levels in serum and breast milk
Number of subjects: 150
Study 15061863 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Information Leaflet (PIL) on oral cancer
Number of subjects: 1525
Study 15061863 — intervention group
Group type: COMPARATOR
Intervention: Control group (questionnaire only)
Number of subjects: 1525
Study 12173999 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium propionate (preservative code 282)
Number of subjects: 27
Study 12173999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 9665188 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of intensive chemotherapy (short arm)
Number of subjects: 248
Study 9665188 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight cycles of intensive chemotherapy (long arm)
Number of subjects: 248
Study 9665188 — intervention group
Group type: COMPARATOR
Intervention: Both treatment arms (short and long)
Number of subjects: 248
Study 10150267 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin 400 mg in 100‐mL solution as an intravenous infusion (1 dose)
Number of subjects: 120
Study 10150267 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin 400 mg in 100‐mL solution as an intravenous infusion (2 doses)
Number of subjects: 120
Study 10150267 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin 400 mg in 100‐mL solution as an intravenous infusion (6 doses)
Number of subjects: 120
Study 10150267 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control Group A)
Number of subjects: 120
Study 2775391 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) for diagnosing meniscal tears
Number of subjects: 23
Study 2775391 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) for diagnosing cruciate ligaments
Number of subjects: 23
Study 1064904 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly-disintegrating tablets with a standardized breakfast meal
Number of subjects: 24
Study 1064904 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release tablets with a standardized breakfast meal
Number of subjects: 24
Study 1064904 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly-disintegrating tablets under fasting conditions
Number of subjects: 24
Study 1064904 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release tablets under fasting conditions
Number of subjects: 24
Study 31431562 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced counseling (training device + smartphone application)
Number of subjects: 371
Study 31431562 — intervention group
Group type: COMPARATOR
Intervention: Verbal counseling
Number of subjects: 371
Study 31431562 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced counseling
Number of subjects: 371
Study 31678957 — intervention group
Group type: EXPERIMENTAL
Intervention: Case Management (CM) plus Usual Intervention (UI)
Number of subjects: 0
Study 31678957 — intervention group
Group type: COMPARATOR
Intervention: Usual Intervention (UI) alone
Number of subjects: 0
Study 28693599 — intervention group
Group type: EXPERIMENTAL
Intervention: 24/7 phone support intervention for 30 days post-discharge
Number of subjects: 286
Study 26443663 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Individual Development Account (IDA) for 6 months with financial incentives for saving
Number of subjects: 700
Study 26443663 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 700
Study 23362174 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 24
Study 23362174 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 24
Study 23362174 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 24
Study 23362174 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine
Number of subjects: 24
Study 23362174 — intervention group
Group type: COMPARATOR
Intervention: Control area (deltoid region)
Number of subjects: 24
Study 21372569 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT score 0-1
Number of subjects: 161
Study 21372569 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT score 2
Number of subjects: 161
Study 21372569 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT score 3
Number of subjects: 161
Study 21372569 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT score 4-5
Number of subjects: 161
Study 21372569 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT score
Number of subjects: 161
Study 19276452 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 643
Study 19276452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study 17915181 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive training (20 sessions, 30-45 minutes each, twice a week)
Number of subjects: 48
Study 17915181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study 16332654 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bread and pasta diet
Number of subjects: 72
Study 16332654 — intervention group
Group type: COMPARATOR
Intervention: Oat and wheat bread and potato diet
Number of subjects: 72
Study 11563466 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol solution
Number of subjects: 695
Study 11563466 — intervention group
Group type: COMPARATOR
Intervention: Vaginal dinoprostone (2mg, two doses administered six hours apart)
Number of subjects: 695
Study 9638409 — intervention group
Group type: COMPARATOR
Intervention: Clamping of the hepatic pedicle
Number of subjects: 0
Study 9638409 — intervention group
Group type: EXPERIMENTAL
Intervention: Total vascular exclusion
Number of subjects: 0
Study 8032457 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone grafts (autografts and allografts)
Number of subjects: 0
Study 8032457 — intervention group
Group type: COMPARATOR
Intervention: Nongrafted sites
Number of subjects: 0
Study 2686422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin 200 mg twice daily
Number of subjects: 52
Study 2686422 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 1 to 2 g every eight to 12 hours
Number of subjects: 52
Study 2686422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin
Number of subjects: 52
Study 2686422 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 52
Study 31053081 — intervention group
Group type: COMPARATOR
Intervention: NoV group (no mechanical ventilation during CPB)
Number of subjects: 420
Study 31053081 — intervention group
Group type: EXPERIMENTAL
Intervention: LOV group (low VT of 3-4 ml/kg IBW, RR of 10-12 acts/min, PEEP of 5-8 cmH2O, FiO2 30%)
Number of subjects: 420
Study 31053081 — intervention group
Group type: EXPERIMENTAL
Intervention: HOV group (low VT of 3-4 ml/kg IBW, RR of 10-12 acts/min, PEEP of 5-8 cmH2O, FiO2 80%)
Number of subjects: 420
Study 27859982 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal-tDCS (1 mA, 20 min)
Number of subjects: 0
Study 27859982 — intervention group
Group type: COMPARATOR
Intervention: Sham-tDCS (30 s)
Number of subjects: 0
Study 25872610 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan treatment for 6 months
Number of subjects: 0
Study 25872610 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan treatment (in independent trials IDNT and IRMA-2)
Number of subjects: 0
Study 24026775 — intervention group
Group type: EXPERIMENTAL
Intervention: Frame-based stereotactic surgical planning system (SSPS)
Number of subjects: 65
Study 24026775 — intervention group
Group type: COMPARATOR
Intervention: Conventional frame-based stereotactics with urokinase thrombolysis
Number of subjects: 65
Study 21488723 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing agent (5% potassium nitrate/2% sodium fluoride)
Number of subjects: 0
Study 21488723 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study 19660004 — intervention group
Group type: COMPARATOR
Intervention: Omalizumab (anti-IgE antibody), subcutaneously administered, dosage not specified, duration of treatment not specified.
Number of subjects: 1933
Study 16828295 — intervention group
Group type: EXPERIMENTAL
Intervention: On pump coronary artery bypass grafting
Number of subjects: 70
Study 16828295 — intervention group
Group type: COMPARATOR
Intervention: Off pump coronary artery bypass grafting
Number of subjects: 70
Study 15244210 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.d., amoxycillin 1000 mg b.d., clarithromycin 500 mg b.d.
Number of subjects: 50
Study 15244210 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg b.d., amoxycillin 1000 mg b.d., clarithromycin 500 mg b.d.
Number of subjects: 50
Study 11831341 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist heat application
Number of subjects: 46
Study 11831341 — intervention group
Group type: COMPARATOR
Intervention: Dry heat application
Number of subjects: 46
Study 9792566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis (CF) patients
Number of subjects: 36
Study 9792566 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease (COPD) patients
Number of subjects: 36
Study 9792566 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 36
Study 9792566 — intervention group
Group type: EXPERIMENTAL
Intervention: All patient groups (CF and COPD)
Number of subjects: 36
Study 7900628 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (angiotensin-converting enzyme inhibitor)
Number of subjects: 0
Study 7900628 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-blocker)
Number of subjects: 0
Study 7900628 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2794839 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (100 mg/cup)
Number of subjects: 12
Study 2794839 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine capsules (100 mg/capsule)
Number of subjects: 12
Study 2794839 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 12
Study 2794839 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 12
Study 2794839 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg)
Number of subjects: 12
Study 2794839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 690226 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana high dose
Number of subjects: 48
Study 690226 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana low dose
Number of subjects: 48
Study 690226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 690226 — intervention group
Group type: COMPARATOR
Intervention: Coltsfoot
Number of subjects: 48
Study 690226 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose marijuana in odor session
Number of subjects: 48
Study 690226 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose marijuana in odor session
Number of subjects: 48
Study 31536112 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 301
Study 31536112 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control
Number of subjects: 301
Study 30702517 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC/EFV on Alternate Days (ATAD)
Number of subjects: 197
Study 30702517 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care (SOC)
Number of subjects: 197
Study 27003457 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid administration
Number of subjects: 130
Study 27003457 — intervention group
Group type: COMPARATOR
Intervention: Saline administration (Control)
Number of subjects: 130
Study 26678938 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol TCI alone
Number of subjects: 100
Study 26678938 — intervention group
Group type: COMPARATOR
Intervention: Propofol TCI plus midazolam and fentanyl
Number of subjects: 100
Study 23177515 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg daily
Number of subjects: 199
Study 23177515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 23177515 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 199
Study 21295286 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily (n = 55)
Number of subjects: 110
Study 21295286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 19369829 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (omeprazole 20 mg once daily, clarithromycin 250 mg twice daily, tinidazole 500 mg twice daily)
Number of subjects: 82
Study 19369829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 19369829 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 82
Study 19369829 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (among H. pylori eradicated patients)
Number of subjects: 82
Study 19369829 — intervention group
Group type: COMPARATOR
Intervention: Placebo (among patients with persistent H. pylori infection)
Number of subjects: 82
Study 16688094 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV + HU (Hydroxyurea 500 mg BID)
Number of subjects: 68
Study 16688094 — intervention group
Group type: COMPARATOR
Intervention: ARV alone
Number of subjects: 68
Study 16688094 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV + HU
Number of subjects: 68
Study 15347128 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (E) and cyclic norethisterone acetate (NETA)
Number of subjects: 16
Study 11773673 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus acupuncture
Number of subjects: 35
Study 11773673 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 35
Study 9255270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, adriamycin and vincristine (CAV)
Number of subjects: 286
Study 9255270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide (PE)
Number of subjects: 286
Study 9255270 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating treatments of CAV and PE
Number of subjects: 286
Study 8510386 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose in the dialysate (GD)
Number of subjects: 8
Study 8510386 — intervention group
Group type: COMPARATOR
Intervention: No glucose in the dialysate (GFD)
Number of subjects: 8
Study 31200280 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional invasive strategy with ischemia targeted reasonably complete coronary revascularization
Number of subjects: 0
Study 31200280 — intervention group
Group type: COMPARATOR
Intervention: Conservative medical therapy
Number of subjects: 0
Study 29476677 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary osmolality in patients with CP (SG)
Number of subjects: 104
Study 29476677 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries experience (DMFT index) in patients with CP (SG)
Number of subjects: 104
Study 29476677 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries risk in patients with CP (SG)
Number of subjects: 104
Study 29476677 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary osmolality cutoff point for SG
Number of subjects: 104
Study 29476677 — intervention group
Group type: COMPARATOR
Intervention: Salivary osmolality cutoff point for CG
Number of subjects: 104
Study 29476677 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between salivary osmolality and DMFT index in SG
Number of subjects: 104
Study 27133564 — intervention group
Group type: EXPERIMENTAL
Intervention: YAB group (200 g of yoghurt supplemented with Bifidobacterium longum during both diet periods)
Number of subjects: 33
Study 27133564 — intervention group
Group type: EXPERIMENTAL
Intervention: YB group (yoghurt only during the balanced diet period)
Number of subjects: 33
Study 27133564 — intervention group
Group type: COMPARATOR
Intervention: CTR group (no yoghurt intake)
Number of subjects: 33
Study 24782624 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent cap group (n = 60)
Number of subjects: 168
Study 24782624 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 108)
Number of subjects: 168
Study 22122709 — intervention group
Group type: EXPERIMENTAL
Intervention: Single layer closure
Number of subjects: 61
Study 22122709 — intervention group
Group type: COMPARATOR
Intervention: Multilayer closure
Number of subjects: 61
Study 20216071 — intervention group
Group type: EXPERIMENTAL
Intervention: Group F (follicular phase)
Number of subjects: 72
Study 20216071 — intervention group
Group type: COMPARATOR
Intervention: Group L (luteal phase)
Number of subjects: 72
Study 18624972 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 1,000 mg alone
Number of subjects: 15
Study 18624972 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) + Dutasteride (D) 0.5 mg/die
Number of subjects: 15
Study 18624972 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) + Letrozole (L) 2.5 mg/die
Number of subjects: 15
Study 16440580 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol solution 50 g/ml, applied twice daily for 8 weeks
Number of subjects: 22
Study 12639589 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar screening scenarios without cost-effectiveness information
Number of subjects: 900
Study 12639589 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar screening scenarios with cost-effectiveness information
Number of subjects: 900
Study 12639589 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliar screening scenarios with cost-effectiveness information
Number of subjects: 900
Study 10569667 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (adenosine receptor antagonist)
Number of subjects: 0
Study 10569667 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 8905484 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-alfentanil (PA group; N = 30)
Number of subjects: 60
Study 8905484 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-alfentanil (MA group; N = 30)
Number of subjects: 60
Study 1804948 — intervention group
Group type: EXPERIMENTAL
Intervention: HFPPV
Number of subjects: 49
Study 1804948 — intervention group
Group type: EXPERIMENTAL
Intervention: PTV
Number of subjects: 49
Study 1804948 — intervention group
Group type: COMPARATOR
Intervention: Both HFPPV and PTV
Number of subjects: 49
Study 6364399 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg tendamistate with 100 g maize meal
Number of subjects: 6
Study 6364399 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg tendamistate with 100 g maize meal
Number of subjects: 6
Study 6364399 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tendamistate with 100 g maize meal
Number of subjects: 6
Study 6364399 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 100 g maize meal
Number of subjects: 6
Study 30194109 — intervention group
Group type: EXPERIMENTAL
Intervention: eTICI 3 (100% reperfusion)
Number of subjects: 801
Study 30194109 — intervention group
Group type: EXPERIMENTAL
Intervention: eTICI 2c (90-99% reperfusion)
Number of subjects: 801
Study 30194109 — intervention group
Group type: EXPERIMENTAL
Intervention: eTICI 2b67 (67-89% reperfusion)
Number of subjects: 801
Study 30194109 — intervention group
Group type: EXPERIMENTAL
Intervention: eTICI 2b50 (50-66% reperfusion)
Number of subjects: 801
Study 30194109 — intervention group
Group type: EXPERIMENTAL
Intervention: eTICI 2a (14-50% reperfusion)
Number of subjects: 801
Study 30194109 — intervention group
Group type: EXPERIMENTAL
Intervention: eTICI 1 (1-14% reperfusion)
Number of subjects: 801
Study 30194109 — intervention group
Group type: EXPERIMENTAL
Intervention: eTICI 0 (no reperfusion)
Number of subjects: 801
Study 30194109 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Rankin Scale shift analyses
Number of subjects: 801
Study 30114726 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Observed Caries Experience (TOCE)
Number of subjects: 0
Study 30114726 — intervention group
Group type: EXPERIMENTAL
Intervention: DMFT
Number of subjects: 0